The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-ups that they view as having a good chance of growing into substantial contributors to the industry. Eli Lilly and Company recently opened its first Gateway Labs location outside of San Francisco and the Deerfield Management-backed health care innovation campus known as Cure in New York City is filling up.
[Sidebar#SC150424]
